NCT01874197 Branched Thoracic Endovascular Grafts for the Treatment of Thoraco-abdominal Aortic
| NCT ID | NCT01874197 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Washington |
| Condition | Thoracoabdominal Aortic Aneurysm, Without Rupture |
| Study Type | INTERVENTIONAL |
| Enrollment | 290 participants |
| Start Date | 2012-08 |
| Primary Completion | 2025-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 290 participants in total. It began in 2012-08 with a primary completion date of 2025-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
An investigator-initiated, prospective, consecutively enrolling, non-randomized single institution clinical evaluation of the safety and effectiveness of branched and fenestrated-branched endovascular stent grafts to preserve branch vessels when used in the treatment of patients with thoraco-abdominal aortic aneurysms. The study evaluates non-FDA-approved off the shelf and custom made branched and fenestrated-branched stent grafts manufactured by Cook Medical. The primary objectives of this study are to determine whether fenestrated-branched and branched endovascular grafts are a safe and effective method of treating patients with thoraco-abdominal aortic aneurysms.
Eligibility Criteria
Inclusion Criteria: All patients must meet all of the following inclusion criteria to be eligible for enrollment into this study: 1. Patient is \> 18 years of age 2. Patients who are male or non-pregnant female (females of child bearing potential must have a negative pregnancy test prior to enrollment into the study) 3. Patient or Legally Authorized Representative has signed an Institutional Review Board (IRB) approved Informed Consent Form 4. Patient is considered by the treating physician to be at high risk of open surgical repair due to one or more major medical co-morbidities (i.e. CAD, CHF, COPD, CRI, advanced age, generalized deconditioning, or other.) with ASA of 3 or more. 5. The patient has a life expectancy of greater than 1 year. 6. The patient has a thoraco-abdominal aortic aneurysm where necessary visceral branch vessels (i.e. the celiac, superior mesenteric, inferior mesenteric, renal and/or dominant spinal arteries) arise from the aneurysm or seal zones necessary for on-label thoracic endovascular repair 7. Patient has a thoraco-abdominal aortic aneurysm that meets at least one of the following: * aneurysm \> 5.5 cm in diameter * aneurysm has increased in size by 0.5 cm in last 6 months * aneurysm is believed to be causing symptoms 8. Patient has sufficient arterial access (femoral and/or iliac) that will allow delivery of the endovascular device with or without the use of a surgical conduit. 9. Patient has suitable proximal (aorta) and distal (aorta or iliac) arteries to allow for adequate fixation and seal: A. Non-aneurysmal proximal aortic seal zone: 1. with a length of 25 mm of proximal seal in non-aneurysmal aorta, with or without coverage of the left subclavian artery, 2. with an outer wall diameter of no less than 20 mm and no greater 38mm, and B. Non-aneurysmal distal aortic or iliac landing zone: 3. With a length of at least 15 mm, 4. Aortic seal zone no less than 15 mm and no greater than 38 mm or Iliac seal zone with an outer wall diameter of no less than 8 mm and no greater than 23 mm. 10\. The patient has no more than 5 necessary visceral arteries that require flow preservation. 11\. All target visceral artery seal zones are \> 4 mm in diameter. 12. Patient must be willing to comply with all required follow-up exams. Exclusion Criteria: Patients that meet ANY of the following are not eligible for enrollment into the study: 1. Patient has an active systemic infection 2. Patient has a mycotic aneurysm. 3. Patient has a known hypersensitivity to contrast media that is not amenable to pre-treatment. 4. Patient has an absolute contra-indication to anticoagulation 5. Patient has a known allergy or intolerance to stainless steel, nickel, or gold 6. Patient has a body habitus that would inhibit adequate X-ray visualization of the aorta 7. Patient has a dominant artery to the spinal cord arising from an area of stent graft coverage that is not amenable to preservation using an endovascular branch 8. Patient is currently participating in another investigational device or drug clinical trial 9. Patient has other medical, social or psychological conditions that, in the opinion of the investigator, preclude them from receiving the pre-treatment, required treatment, and post-treatment procedures and evaluations. 10. Patient has a freely ruptured TAAA with hemodynamic instability 11. Patient has unstable angina (defined as angina with a progressive increase in symptoms, new onset at rest or nocturnal angina, or onset of prolonged angina) 12. Patient has had a major surgical or interventional procedure unrelated to the treatment of the aneurysm planned within 30 days of the TAAA repair. Adjunctive procedures for treatment of the TAAA (i.e. carotid-subclavian bypass or iliac conduit) are acceptable. 13. Patient has a history of connective tissue disease (e.g. Marfan or Ehlers Danlos syndromes)
Contact & Investigator
Matthew P Sweet, MD
PRINCIPAL INVESTIGATOR
University of Washington
Frequently Asked Questions
Who can join the NCT01874197 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Thoracoabdominal Aortic Aneurysm, Without Rupture. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT01874197 currently recruiting?
Yes, NCT01874197 is actively recruiting participants. Contact the research team at BTEVAR@uw.edu for enrollment information.
Where is the NCT01874197 trial being conducted?
This trial is being conducted at Seattle, United States.
Who is sponsoring the NCT01874197 clinical trial?
NCT01874197 is sponsored by University of Washington. The principal investigator is Matthew P Sweet, MD at University of Washington. The trial plans to enroll 290 participants.